Cara Therapeutics (CARA) Scheduled to Post Quarterly Earnings on Monday

Cara Therapeutics (NASDAQ:CARA) will be posting its quarterly earnings results after the market closes on Monday, May 13th. Analysts expect Cara Therapeutics to post earnings of ($0.38) per share for the quarter.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Monday, March 4th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.02). Cara Therapeutics had a negative net margin of 565.21% and a negative return on equity of 122.10%. The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $2.34 million. During the same period in the previous year, the company posted ($0.56) earnings per share. On average, analysts expect Cara Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cara Therapeutics Trading Up 2.4 %

Shares of NASDAQ CARA traded up $0.02 during midday trading on Tuesday, reaching $0.81. 117,503 shares of the company were exchanged, compared to its average volume of 606,535. The stock has a fifty day simple moving average of $0.83 and a 200 day simple moving average of $0.85. The stock has a market cap of $44.24 million, a P/E ratio of -0.36 and a beta of 0.74. Cara Therapeutics has a 1 year low of $0.50 and a 1 year high of $4.67.

Analysts Set New Price Targets

Several equities research analysts have recently commented on CARA shares. StockNews.com cut Cara Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Canaccord Genuity Group reduced their target price on shares of Cara Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, March 6th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $5.00 price target on shares of Cara Therapeutics in a research note on Wednesday, April 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $9.75.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.